SEARCH

SEARCH BY CITATION

References

  • 1
    Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991; 100: 9981005.
  • 2
    Camilleri M, Choi MG. Review article: Irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 315.
  • 3
    Lanng C, Mortensen D, Friis M, et al. Gastrointestinal dysfunction in a community sample of subjects with symptoms of irritable bowel syndrome. Digestion 2003; 67: 149.
  • 4
    Houghton LA, Lea R, Jackson N, Whorwell PJ. The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut 2002; 50: 4714.
  • 5
    Gershon MD. Review article: Roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13 (Suppl. 2): 1530.
  • 6
    Turvill JL, Farthing MJ. Effect of granisetron on cholera toxin-induced enteric secretion. Lancet 1997; 349: 1293.
  • 7
    Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66: 26214.
  • 8
    Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 152731.
  • 9
    Heitkemper MM, Kohen R, Jarrett ME, Cain KC, Burr RL, Poppe A. Association of SERT polymorphism with psychological distress, symptoms and predominant stool group in women with irritable bowel syndrome. Gastroenterology 2005; 4: A59.
  • 10
    Yeo A, Boyd P, Lumsden S, et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut 2004; 53: 14528.
  • 11
    Pata C, Erdal ME, Derici E, Yazar A, Kanik A, Ulu O. Serotonin transporter gene polymorphism in irritable bowel syndrome. Am J Gastroenterol 2002; 97: 17804.
    Direct Link:
  • 12
    Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002; 123: 42532.
  • 13
    Lee DY, Park H, Kim WH, Lee SI, Seo YJ, Choi YC. Serotonin transporter gene polymorphism in healthy adults and patients with irritable bowel syndrome. Korean J Gastroenterol 2004; 43: 1822.
  • 14
    Kim HJ, Camilleri M, Carlson PJ, et al. Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 2004; 53: 82937.
  • 15
    Park JM, Choi MG, Park JA, et al. Serotonin transporter gene polymorphism and irritable bowel syndrome. Neurogastroenterol Motil 2006; 18: 9951000.
  • 16
    Li Y, Nie Y, Xie J, et al. The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients. Dig Dis Sci 2007; Epub ahead of print
  • 17
    Collier DA., Stober G, Li T, et al. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry 1996; 1: 45360.
  • 18
    Freeman SL, Glatzle J, Robin CS, et al. Ligand-induced 5-HT(3) receptor internalization in enteric neurons in rat ileum. Gastroenterology 2006; 131: 97107.
  • 19
    Liu MT, Rayport S, Jiang Y, Murphy DL, Gershon MD. Expression and function of 5-HT3 receptors in the enteric neurons of mice lacking the serotonin transporter. Am J Physiol Gastrointest Liver Physiol 2002; 283: G1398411.
  • 20
    Xu J, Turner A, Little J, Bleecker ER, Meyers DA. Positive results in association studies are associated with departure from Hardy-Weinberg equilibrium: hint for genotyping error? Hum Genet 2002; 111: 5734.
  • 21
    Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J Clin Gastroenterol 2005; 39: S18493.
  • 22
    Camilleri M. Is there a SERT-ain association with IBS? Gut 2004; 53: 13969.
  • 23
    Gershon MD. 5-HT (serotonin) physiology and related drugs. Curr Opin Gastroenterol 2000; 16: 11320.
  • 24
    Andresen V, Camilleri M. Irritable bowel syndrome: recent and novel therapeutic approaches. Drugs 2006; 66: 107388.
  • 25
    Park MI, Camilleri M. Genetics and genotypes in irritable bowel syndrome: implications for diagnosis and treatment. Gastroenterol Clin North Am 2005; 34: 30517.
  • 26
    Holtmann G. IBS: a syndrome or many diseases? Best Pract Res Clin Gastroenterol 2004; 18 (Suppl.): 917.
  • 27
    Murphy DL, Lerner A, Rudnick G, Lesch KP. Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol Interv 2004; 4: 10923.
  • 28
    Camilleri M. Pharmacogenomics and functional gastrointestinal disorders. Pharmacogenomics 2005; 6: 491501.
  • 29
    Gershon MD. Plasticity in serotonin control mechanisms in the gut. Curr Opin Pharmacol 2003; 3: 6007.
  • 30
    Blakely RD. Physiological genomics of antidepressant targets: keeping the periphery in mind. J Neurosci 2001; 21: 831923.
  • 31
    McLaughlin J, Houghton LA. The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome. Expert Opin Drug Saf 2006; 5: 31327.
  • 32
    Levy RL, Olden KW, Naliboff BD, et al. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology 2006; 130: 144758.
  • 33
    Mawe GM, Coates MD, Moses PL. Review article: Intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther 2006; 23: 106776.
  • 34
    Spiller R, Campbell E. Post-infectious irritable bowel syndrome. Curr Opin Gastroenterol 2006; 22: 137.
  • 35
    Saito YA, Petersen GM, Locke GR III, Talley NJ. The genetics of irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 105765.
  • 36
    Lazaridis KN, Juran BD. American Gastroenterological Association future trends committee report: the application of genomic and proteomic technologies to digestive disease diagnosis and treatment and their likely impact on gastroenterology clinical practice. Gastroenterology 2005; 129: 172052.
  • 37
    Camilleri M. Mechanisms in IBS: something old, something new, something borrowed. Neurogastroenterol Motil 2005; 17: 3116.
  • 38
    Drossman DA. What does the future hold for irritable bowel syndrome and the functional gastrointestinal disorders? J Clin Gastroenterol 2005; 39: S2516.
  • 39
    Gershon MD. Review article: Serotonin receptors and transporters – roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004; 20 (Suppl. 7): 314.
  • 40
    Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132: 397414.
  • 41
    Spiller R, Bennett A. Searching for the answer to irritable bowel syndrome in the colonic mucosa: SERTainty and unSERTainty. Gastroenterology 2007; 132: 43741.
  • 42
    Azpiroz F, Bouin M, Camilleri M, et al. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil 2007; 19: 6288.
  • 43
    Ouyang A, Wrzos HF. Contribution of gender to pathophysiology and clinical presentation of IBS: should management be different in women? Am J Gastroenterol 2006; 101: S6029.
    Direct Link:
  • 44
    Ohman L, Simren M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Dig Liver Dis 2007; 39: 20115.
  • 45
    Adam B, Liebregts T, Holtmann G. Mechanisms of disease: genetics of functional gastrointestinal disorders – searching the genes that matter. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 10210.
  • 46
    Geeraerts B, Van OL, Tack J. Serotonin transporter gene polymorphisms in irritable bowel syndrome. Neurogastroenterol Motil 2006; 18: 9579.
  • 47
    Youssef NN, Di LC. Pediatric gastrointestinal motility – future directions and challenges. Dig Dis 2006; 24: 30812.
  • 48
    Chitkara DK, Di LC. From the bench to the ‘crib’-side: implications of scientific advances to paediatric neurogastroenterology and motility. Neurogastroenterol Motil 2006; 18: 25162.
  • 49
    Camilleri CE, Carlson PJ, Camilleri M, et al. A study of candidate genotypes associated with dyspepsia in a U.S. community. Am J Gastroenterol 2006; 101: 58192.
    Direct Link:
  • 50
    Campo JV, Dahl RE, Williamson DE, Birmaher B, Perel JM, Ryan ND. Gastrointestinal distress to serotonergic challenge: a risk marker for emotional disorder? J Am Acad Child Adolesc Psychiatry 2003; 42: 12216.
  • 51
    Ojima K, Watanabe N, Narita N, Narita M. Temporomandibular disorder is associated with a serotonin transporter gene polymorphism in the Japanese population. Biopsychosoc Med 2007; 1: 3.
  • 52
    Bellini M, Rappelli L, Blandizzi C, et al. Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. Am J Gastroenterol 2003; 98: 270511.
    Direct Link:
  • 53
    Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 165764.
  • 54
    Tack J, Broekaert D, Corsetti M, Fischler B, Janssens J. Influence of acute serotonin reuptake inhibition on colonic sensorimotor function in man. Aliment Pharmacol Ther 2006; 23: 26574.
  • 55
    Scherl E, Frissora CL. Irritable bowel syndrome genophenomics: correlation of serotonin-transporter polymorphisms and alosetron response. Pharmacogenomics J 2003; 3: 646.
  • 56
    Iceta R, Mesonero JE, Aramayona JJ, Alcalde AI. Molecular characterization and intracellular regulation of the human serotonin transporter in Caco-2 cells. J Physiol Pharmacol 2006; 57: 11930.
  • 57
    Dinan TG, Quigley EM, Ahmed SM, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 30411.
  • 58
    Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006; 130: 3443.
  • 59
    Grider JR. Desensitization of the peristaltic reflex induced by mucosal stimulation with the selective 5-HT4 agonist tegaserod. Am J Physiol Gastrointest Liver Physiol 2006; 290: G31927.
  • 60
    Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 34957.
  • 61
    Park H, Ji SW, Lee DY, Lee SI. Serotonin transporter gene polymorphism and its relationship to plasma serotonin in irritable bowel syndrome. Gastroenterology 2004; 126: A217.
  • 62
    Smout AJ, Azpiroz F, Brummer RJ, et al. Technologies in the evaluation of irritable bowel syndrome. Digestion 2004; 69: 15865.
  • 63
    Franke L, Schewe HJ, Uebelhack R, Berghofer A, Muller-Oerlinghausen B. Platelet-5HT uptake and gastrointestinal symptoms in patients suffering from major depression. Life Sci 2003; 74: 52131.
  • 64
    Ozsarac N, Santha E, Hoffman BJ. Alternative non-coding exons support serotonin transporter mRNA expression in the brain and gut. J Neurochem 2002; 82: 33644.
  • 65
    Camilleri M, Andrews CN, Bharucha AE, et al. Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology 2007; 132: 1725.
  • 66
    Ismair MG, Kullak-Ublick GA, Blakely RD, Fried M, Vavricka SR. Tegaserod inhibits the serotonin transporter SERT. Digestion 2007; 75: 905.
  • 67
    Foley KF, Pantano C, Ciolino A, Mawe GM. IFN-gamma and TNF-alpha decrease serotonin transporter function and expression in Caco2 cells. Am J Physiol Gastrointest Liver Physiol 2007; 292: G77984.
  • 68
    Shufflebotham J, Hood S, Hendry J, et al. Acute tryptophan depletion alters gastrointestinal and anxiety symptoms in irritable bowel syndrome. Am J Gastroenterol 2006; 101: 25827.
    Direct Link:
  • 69
    Meier Y, Eloranta JJ, Darimont J, et al. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos 2007; 35: 5904.
  • 70
    Chan AO, Lam KF, Hui WM, et al. Influence of positive family history on clinical characteristics of functional constipation. Clin Gastroenterol Hepatol 2007; 5: 197200.
  • 71
    Chan AO, Hui WM, Lam KF, et al. Familial aggregation in constipated subjects in a tertiary referral center. Am J Gastroenterol 2007; 102: 14952.
    Direct Link:
  • 72
    Tian XY, Bian ZX, Hu XG, Zhang XJ, Liu L, Zhang H. Electro-acupuncture attenuates stress-induced defecation in rats with chronic visceral hypersensitivity via serotonergic pathway. Brain Res 2006; 1088: 1018.
  • 73
    Coates MD, Johnson AC, Greenwood-Van MB, Mawe GM. Effects of serotonin transporter inhibition on gastrointestinal motility and colonic sensitivity in the mouse. Neurogastroenterol Motil 2006; 18: 46471.
  • 74
    Wheatcroft J, Wakelin D, Smith A, Mahoney CR, Mawe G, Spiller R. Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Neurogastroenterol Motil 2005; 17: 86370.
  • 75
    Cornelissen LL, Brooks DP, Wibberley A. Female, but not male, serotonin reuptake transporter (5-HTT) knockout mice exhibit bladder instability. Auton Neurosci 2005; 122: 10710.
  • 76
    Linden DR, Foley KF, McQuoid C, Simpson J, Sharkey KA, Mawe GM. Serotonin transporter function and expression are reduced in mice with TNBS-induced colitis. Neurogastroenterol Motil 2005; 17: 56574.
  • 77
    Magro F, Fraga S, Azevedo I, Soares-da-Silva P. Intestinal 5-hydroxytryptamine and mast cell infiltration in rat experimental colitis. Dig Dis Sci 2006; 51: 495501.
  • 78
    Ropenga A, Combes O, Chapel A, Griffiths NM. Persistence of altered 5-hydroxytryptamine turnover following hemibody X-irradiation in the rat distal colon. Int J Radiat Biol 2004; 80: 399411.
  • 79
    Chen JJ, Li Z, Pan H, et al. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J Neurosci 2001; 21: 634861.
  • 80
    Ren TH, Wu J, Yew D, et al. Effects of neonatal maternal separation on neurochemical and sensory response to colonic distension in a rat model of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2007; 292: G84956.
  • 81
    Lomax AE, O’Hara JR, Hyland NP, Mawe GM, Sharkey KA. Persistent alterations to enteric neural signaling in the guinea pig colon following the resolution of colitis. Am J Physiol Gastrointest Liver Physiol 2007; 292: G48291.
  • 82
    Wang BM, Wang YM, Zhang WM, et al. Serotonin transporter gene polymorphism in irritable bowel syndrome. Zhonghua Nei Ke Za Zhi 2004; 43: 43941.
  • 83
    Saito YA, Locke GR III, Zimmerman JM, et al. A genetic association study of 5-HTT LPR and GNbeta3 C825T polymorphisms with irritable bowel syndrome. Neurogastroenterol Motil 2007; 19: 46570.
  • 84
    Niesler B, Fell C, Kapeller J, et al. SERT-P Polymorphism in the serotonin transporter gene and irritable bowel syndrome: what’s going on? Gastroenterology 2007; 132 (4 Suppl. 2): A675.